Sep 2020 – EyRIS was awarded a 5-year contract for the deployment of SELENA+, an deep learning system to detect diabetic retinopathy, glaucoma and age-related macular degeneration in the Singapore Integrated Diabetic Retinopathy Program (SiDRP). This award is not only a milestone for EyRIS but also a world first in showcasing real world adoption of an artificial intelligence medical device in a national screening program.
SELENA+ attained its regulatory approval by the Singapore’s Health Science Authority (HSA) in Oct 2019, European CE Mark in March 2020 and Medical Device Authority of Malaysia in June 2020. This award-winning product was recently cited as one of five projects to be implemented under National AI Strategy unveiled by the Singapore government.
When SELENA+ goes live in November 2020, it will be initially deployed to screen 120,000 patients per year. The autonomous AI identifies images that require intervention which was traditionally performed by human graders. This will in turn make the screening process faster and more consistent, translating into reduction of workload and cost savings.
EyRIS’s SELENA+ is also deployed in 23 private optometric practices in Singapore on the “Say No To Vision Loss” platform.
New IPO: ES Sunlogy Berhad, a provider of mechanical and electrical (M&E) engineering services and renewable energy solutions, aims to list on the ACE Market!
MQ Trader 226 views | 1 d ago
0:17
New IPO: Techstore Berhad, an IT security and automation solutions provider, aims to list on the ACE Market!
MQ Trader 470 views | 3 d ago
0:17
New IPO: Richtech Digital Berhad, a distributor of electronic reloads and digital payment solutions, aims to list on the ACE Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Tuapui
469 posts
Posted by Tuapui > 2020-09-18 14:33 | Report Abuse
see can break 10c or not.